Role of FDG-PET/CT in the assessment of suspected recurrent breast cancer

 


Our study evaluated the role of FDG-PET/CT in the assessment of suspected recurrent breast cancer in 46 patients presenting with elevated serum tumor markers 1-21 years after their initial diagnosis, of whom 30 patients were diagnosed with tumor recurrence and 16 showed no further evidence of disease.

PET/CT had an overall sensitivity, specificity and accuracy of 90%, 71% and 83%, respectively.  In 37 patients PET/CT was compared with contrast-enhanced CT and had higher sensitivity (85% vs. 70%), specificity (76% vs. 47%) and accuracy (81% vs. 59%).

In addition, PET/CT had an impact on the management of 24 patients (51%): chemo-or radiotherapy was started in 16 patients, treatment was modified in two patients and six patients were referred to biopsy, followed by referral to surgery in two.

In conclusion, integrated FDG-PET/CT is a sensitive and accurate imaging modality and is superior to CT for the diagnosis of tumor recurrence in patients with breast cancer and rising tumor markers. PET/CT appears to have a role in determining the subsequent clinical management in these patients.  

 

Bibliographic reference:

Radan L et al.: "The role of FDG-PET/CT in suspected recurrence of breast cancer", Cancer. 2006 Oct 24; [Epub ahead of print]

 

Simona Ben-Haim
Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel